VEON Ltd. (NASDAQ, Euronext Amsterdam: VEON) (“VEON” or the “Company”), a global digital operator that provides converged connectivity and online services, today provides an update on the timing of the ratio change under the Company’s ADR program, previously announced on 6 February 2023 and originally planned to become effective on 6 March 2023. The Company was informed late afternoon on Friday 3 March 2023 by BNY Mellon that the ratio change effectiveness has been postponed as The Depository Trust & Clearing Corporation (“DTCC“) was not prepared to make the new CUSIP with new ratio available on Monday, 6 March 2023 as scheduled. The Company awaits further confirmation from DTCC as to when it will be prepared to make the new CUSIP with new ratio available and will announce the new timing for effectiveness as soon as this is confirmed.
Scorpion Capital Tweets “We Expect To Submit And Release Our $HRMY FDA Citizen’s Petition By Monday, Perhaps Sooner. We’re Incorporating Additional Evidence Of The Drug’s Toxicity And Lack Of Efficacy….”
https://twitter.com/ScorpionFund/status/1641086021407260675
We expect to submit and release our $HRMY FDA Citizen’s Petition by Monday, perhaps sooner. We’re incorporating additional evidence of the
